Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

@article{Rovin2012EfficacyAS,
  title={Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.},
  author={Brad H. Rovin and Richard A. Furie and Kevin Latinis and Richard John Looney and Fernando C Fervenza and Jorge S{\'a}nchez-Guerrero and Romeo Maciuca and David Zhang and Jay P Garg and Paul G Brunetta and Gerald B. Appel},
  journal={Arthritis and rheumatism},
  year={2012},
  volume={64 4},
  pages={1215-26}
}
OBJECTIVE To evaluate the efficacy and safety of rituximab in a randomized, double-blind, placebo-controlled phase III trial in patients with lupus nephritis treated concomitantly with mycophenolate mofetil (MMF) and corticosteroids. METHODS Patients (n = 144) with class III or class IV lupus nephritis were randomized 1:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. The primary end point was renal response status at week 52. RESULTS Rituximab depleted peripheral… CONTINUE READING
Highly Influential
This paper has highly influenced 22 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 33 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 247 extracted citations

Biotherapies in systemic lupus erythematosus: New targets.

Joint, bone, spine : revue du rhumatisme • 2017
View 10 Excerpts
Highly Influenced

Mycophenolate mofetil for lupus nephritis: an update.

Expert review of clinical immunology • 2015
View 20 Excerpts
Highly Influenced

Emerging biological therapies for systemic lupus erythematosus.

Expert opinion on emerging drugs • 2014
View 4 Excerpts
Highly Influenced

Biological and targeted therapies of systemic lupus erythematosus: evidence and the state of the art.

Expert review of clinical immunology • 2017
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 56 references

Aspreva Lupus Management Study (ALMS): extra-renal activity results from the maintenance phase [abstract

DA Isenberg, GB Appel, +3 authors D Wofsy
Arthritis Rheum • 2010

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2010

Similar Papers

Loading similar papers…